These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 34567939)
1. Pathological eradication of recurrent metastatic renal cell carcinoma with sarcomatoid component by nivolumab plus ipilimumab combination therapy. Sejima T; Masago T; Yoshida M; Nishi T; Kawabata Y; Tajima Y; Yumioka T; Honda M; Takenaka A Int Cancer Conf J; 2021 Oct; 10(4):285-289. PubMed ID: 34567939 [TBL] [Abstract][Full Text] [Related]
2. Complete response to combination therapy using nivolumab and ipilimumab for metastatic, sarcomatoid collecting duct carcinoma presenting with high expression of programmed death-ligand 1: a case report. Fuu T; Iijima K; Kusama Y; Otsuki T; Kato H J Med Case Rep; 2022 May; 16(1):193. PubMed ID: 35581611 [TBL] [Abstract][Full Text] [Related]
3. Salvage ipilimumab associated with a significant response in sarcomatoid renal cell carcinoma. George G; Schmidt L; Tolat P; Riese M; Kilari D J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32114501 [TBL] [Abstract][Full Text] [Related]
4. The Role of Cytoreductive Nephrectomy in Renal Cell Carcinoma with Sarcomatoid Histology: A Case Series and Review of the Literature. Studentova H; Rusarova N; Ondruskova A; Zemankova A; Student V; Skanderova D; Melichar B Curr Oncol; 2022 Aug; 29(8):5475-5488. PubMed ID: 36005171 [TBL] [Abstract][Full Text] [Related]
5. Sarcomatoid renal cell carcinoma with an inferior vena cava tumor thrombus that was completely resected by robot-assisted laparoscopic radical nephrectomy after neoadjuvant therapy nivolumab plus ipilimumab: a case report. Tsuchiyama A; Ohba K; Nakanishi H; Yasuda T; Nakamura Y; Kurohama H; Mitsunari K; Matsuo T; Mochizuki Y; Imamura R Int Cancer Conf J; 2024 Jan; 13(1):6-10. PubMed ID: 38187173 [TBL] [Abstract][Full Text] [Related]
6. Nivolumab plus ipilimumab induced endocrinopathy and acute interstitial nephritis in metastatic sarcomatoid renal-cell carcinoma: A case report and review of literature. Hino C; Nishino K; Pham B; Jeon WJ; Nguyen M; Cao H Front Immunol; 2022; 13():993622. PubMed ID: 36052087 [TBL] [Abstract][Full Text] [Related]
7. Impact of Cytoreductive Nephrectomy Following Nivolumab Plus Ipilimumab Therapy for Patients With Advanced Renal Cell Carcinoma. Shirotake S; Miyama YU; Baba Y; Tajima H; Okada Y; Nakazawa K; Usami Y; Yasuda M; Igarashi D; Kaneko GO; Kanao K; Oyama M; Nishimoto K Anticancer Res; 2022 May; 42(5):2727-2735. PubMed ID: 35489743 [TBL] [Abstract][Full Text] [Related]
8. Complete response of metastatic renal cell carcinoma with inferior vena cava tumor thrombus to nivolumab plus ipilimumab. Hayashida M; Miura Y; Noda T; Yamanaka T; Tanaka N; Yasuoka S; Oka S; Sakaguchi K; Kinowaki K; Urakami S IJU Case Rep; 2022 Jul; 5(4):268-272. PubMed ID: 35795114 [TBL] [Abstract][Full Text] [Related]
9. A Pathological Complete Response to the Combination of Ipilimumab and Nivolumab in a Patient with Metastatic Renal Cell Carcinoma. Studentova H; Zemankova A; Spisarova M; Skanderova D; Tudos Z; Melichar B; Student V Medicina (Kaunas); 2022 Feb; 58(3):. PubMed ID: 35334512 [No Abstract] [Full Text] [Related]
10. Cytoreductive Nephrectomy After Combination of Nivolumab Plus Ipilimumab for Mucinous Tubular and Spindle Cell Carcinoma of the Kidney With Bone Metastases: A Case Report. Furubayashi N; Taguchi K; Negishi T; Miura A; Sato Y; Miyoshi M; Nakamura M In Vivo; 2022; 36(1):510-521. PubMed ID: 34972756 [TBL] [Abstract][Full Text] [Related]
11. Safe and effective use of nivolumab plus ipilimumab in a patient with metastatic clear-cell renal cell carcinoma with sarcomatoid dedifferentiation and end stage renal disease on hemodialysis. Shaw LK; Wiele AJ; Sircar K; Wood CG; Msaouel P Cancer Treat Res Commun; 2021; 27():100349. PubMed ID: 33725559 [TBL] [Abstract][Full Text] [Related]
12. Three Cases of Nivolumab Plus Ipilimumab Therapy in Haemodialysis Patients With Metastatic Renal Cell Carcinoma. Kobari Y; Yoshida K; Iizuka J; Kondo T; Ishida H; Tanabe K; Takagi T In Vivo; 2021; 35(6):3585-3589. PubMed ID: 34697199 [TBL] [Abstract][Full Text] [Related]
13. Two cases of nivolumab plus ipilimumab therapy for dialysis patients with advanced bone metastasis from renal cell carcinoma. Takahashi M; Takishita M; Yamazato Y; Kakinoki H; Udo K; Tobu S; Noguchi M CEN Case Rep; 2023 May; 12(2):237-241. PubMed ID: 36402939 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of Cabozantinib in Metastatic Papillary Renal Cell Carcinoma Following Ineffective Treatment With Initial Therapy of Nivolumab and Ipilimumab. Tachibana H; Ishiyama Y; Yoshino M; Yamashita K; Toki D; Kondo T In Vivo; 2021; 35(3):1743-1747. PubMed ID: 33910858 [TBL] [Abstract][Full Text] [Related]
15. Complete pathologic response after laparoscopic hepatectomy following treatment with nivolumab and ipilimumab for anticancer drug-resistant MSI-high colon cancer liver metastasis consisting of poorly differentiated adenocarcinoma with squamous differentiation: A case report. Kato M; Sawayama H; Komohara Y; Hisano Y; Nakamura H; Ohuchi M; Ogawa K; Miyamoto Y; Yoshida N; Baba H Clin J Gastroenterol; 2024 Feb; 17(1):57-64. PubMed ID: 37874527 [TBL] [Abstract][Full Text] [Related]
16. [A Case of Metastatic Renal Cell Carcinoma with Arthritis and Colitis Due to Immune-Related Adverse Events During Ipilimumab-Nivolumab Combination Therapy]. Toyoshima M; Ikarashi D; Tsuboi H; Moriwaka M; Tamada S; Matsuura T; Maekawa S; Kato R; Kanehira M; Takata R; Sugimura J; Obara W Hinyokika Kiyo; 2023 Aug; 69(8):227-232. PubMed ID: 37667600 [TBL] [Abstract][Full Text] [Related]
17. A case of multiple metastatic sarcomatoid renal cell carcinoma with complete response to nivolumab. Tomioka M; Nakane K; Ozawa K; Iinuma K; Suzui N; Miyazaki T; Koie T Cancer Rep (Hoboken); 2021 Aug; 4(4):e1356. PubMed ID: 33656804 [TBL] [Abstract][Full Text] [Related]
18. Efficacy of nivolumab plus ipilimumab as first-line therapy for primary tumors in patients with renal cell carcinoma. Kikuchi H; Osawa T; Matsumoto R; Abe T; Maruyama S; Harabayashi T; Miyata H; Kashiwagi A; Ikeshiro S; Sazawa A; Fukui R; Morita K; Takeuchi I; Hori K; Yamashita N; Minami K; Mochizuki T; Murai S; Shinohara N Urol Oncol; 2022 Jan; 40(1):13.e19-13.e27. PubMed ID: 34716079 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma. Tannir NM; Signoretti S; Choueiri TK; McDermott DF; Motzer RJ; Flaifel A; Pignon JC; Ficial M; Frontera OA; George S; Powles T; Donskov F; Harrison MR; Barthélémy P; Tykodi SS; Kocsis J; Ravaud A; Rodriguez-Cid JR; Pal SK; Murad AM; Ishii Y; Saggi SS; McHenry MB; Rini BI Clin Cancer Res; 2021 Jan; 27(1):78-86. PubMed ID: 32873572 [TBL] [Abstract][Full Text] [Related]
20. First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium. Dudani S; Graham J; Wells JC; Bakouny Z; Pal SK; Dizman N; Donskov F; Porta C; de Velasco G; Hansen A; Iafolla M; Beuselinck B; Vaishampayan UN; Wood LA; Liow E; Yan F; Yuasa T; Bjarnason GA; Choueiri TK; Heng DYC Eur Urol; 2019 Dec; 76(6):861-867. PubMed ID: 31445844 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]